Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Biol Ther. 2012 Dec;13(14):1374-5. doi: 10.4161/cbt.22010. Epub 2012 Sep 6.

Loss of OATP1B3 function causes Rotor syndrome: implications for potential use of inhibitors in cancer.

Author information

  • 1Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute; Bethesda, MD 20892, USA.

Abstract

There has been increasing recognition that organic anion transporter proteins (OATPs) play an important role in the biology of various cancers. De novo expression of OATPs has been identified in breast, colon, pancreatic, gastric and prostate cancer cells, among others. In patients with prostate cancer, polymorphisms encoding decreased functioning OATP1B3 were associated with a longer time to progression on androgen deprivation therapy and a longer overall survival which is likely caused by reduced tumoral testosterone uptake. Because of these findings, therapeutic inhibition targeting OATP1B3 has been proposed. However, any enthusiasm for inhibiting OATP1Bs therapeutically has been tempered by reservations about potential consequences. For instance, inhibitors could interfere with several normal physiological processes mediated by OATP1B3 (i.e., bile acid reuptake, bilirubin uptake, etc) or cause potential, as-yet unknown, drug interactions by barring hepatic uptake, subsequent metabolism and elimination.

PMID:
22954695
[PubMed - indexed for MEDLINE]
PMCID:
PMC3542226
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Write to the Help Desk